Hellman Jordan Management Company’s Ginkgo Bioworks DNA Stock Holding History

Hellman Jordan Management Company’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,575	Closed	-$150K	–	50
2022 Q2	$150K	Buy	1,575 +575	+58%	+$70.1K	0.2%	53
2022 Q1	$161K	Hold	1,000	–	–	0.17%	61
2021 Q4	$332K	Buy	+1,000	New	+$475K	0.4%	56

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Hellman Jordan Management Company's DNA Position: Q3 2022 in Review

Hellman Jordan Management Company sold out of Ginkgo Bioworks (DNA) in Q3 2022, closing a stake of 1,575 shares — an estimated $150K sold.

Hellman Jordan Management Company first reported a position in DNA in Q4 2021 and held it in 3 quarters. The position peaked at $332K in Q4 2021. 278 funds tracked by Wall St. Rank hold DNA as of Q3 2022.

Hellman Jordan Management Company reported no remaining Ginkgo Bioworks position as of Q3 2022 after selling out during the quarter.
Hellman Jordan Management Company sold 1,575 Ginkgo Bioworks shares in Q3 2022, an estimated $150K.
Hellman Jordan Management Company first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 3 quarters.
Hellman Jordan Management Company's Ginkgo Bioworks position peaked at $332K in Q4 2021.
278 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2022.

Based on Hellman Jordan Management Company's 13F filing for Q3 2022, filed 13 Oct 2022.